The Medical Need for Mino-Lok – Citius Pharmaceuticals

The Medical Need for Mino-Lok®

Professional medical feedback suggests that there is an important need to develop an alternative to the standard of care for catheter-related bloodstream infections (CRBSIs). Of the approximately 7 million central venous catheters (CVCs) used annually, about 500,000, or 7%, become infected, leading to serious, life-threatening infections.

Who is at Risk for Catheter-Related Bloodstream Infections (CRBSIs)?

Certain patient populations are at particularly high risk for complications resulting from CRBSIs, including:

  • Cancer and hemodialysis patients with long-term surgically implantable silicone catheters. Removal of the CVC and reinsertion of a new one at a different site may be difficult, or even impossible, because of the unavailability of other accessible vascular sites and the need to maintain infusion therapy.
  • Critically ill patients with short-term catheters who have underlying coagulopathy, where the blood’s ability to clot is impaired. This condition makes reinsertion of a new CVC at a different site risky in terms of mechanical complications, such as hemopneumothorax, misplacement, or arterial puncture.

The standard of care in the management of CRBSIs consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. These procedures are costly, and 15% to 20% of the procedures are associated with significant morbidity. There are currently no approved therapies to salvage infected CVCs.